PositiveID
Subsidiary Chief Science Officer
Delivers Co-Authored Report
to U.S. Department of Defense on
Agroterrorism Threat
"Defending
Against Agroterrorism: Modeling Pathogen Dispersion Pathways"
applies onsite pathogen detection expertise of the former chief
scientist of Dept. of Homeland Security, Office of Health
Affairs, and Chief Veterinarian
Delray Beach, FL
-- May 08, 2018 -- InvestorsHub NewsWire
-- PositiveID Corporation ("PositiveID" or "Company")
(OTC:PSIDD),
ExcitePCR subsidiary today
announced publication of a report co-authored by
its
chief
science
officer
(CSO), Kimothy Smith, DVM, Ph.D., for the
U.S. Dept of
Defense-sponsored Homeland Defense & Security
Information Analysis Center.
The report describes the
potential dangers of a bioterrorism event and explains why rapid,
patient-side diagnostics may be the most important defense
against the
deliberate introduction of plant or animal disease into U.S.
agriculture to generate collective fear, cause economic loss, and
undermine social stability.
Key high-threat bioagents
are "zoonoses," infectious diseases that can be
transferred
from animals to humans, like rabies, anthrax, Lyme disease, and
West Nile virus.
The report further states
quick deployment of user-friendly
diagnostics is critical to successful containment of an
agroterrorism event.
Prior to his move
to the private
sector in 2008, Dr. Smith was the Senior Advisor for International
Biodefense for the Department of Homeland Security (DHS), Office of
Health Affairs. In that role
he served as
detailee to the Office of International Health & Biodefense of
the U.S. State Department.
During this period, as an
expert specialist he
coordinated
biodefense and emergency response strategies with international
partners and facilitated dialogue on food safety and
agricultural security. He also served
as Acting Director
of the National Biosurveillance Integration
Center.
PositiveID's ExcitePCR
subsidiary is developing the FireflyDX family of products
to
provide
automated, real-time pathogen detection at the point
of care/point of need (POC/PON), faster and less expensively than
existing devices.
FireflyDX's onsite
pathogen detection applications
are expected
to include human clinical, such as
infectious disease,
and hospital acquired infections, global food and agricultural
screening, and biological warfare and
biothreat defense.
About PositiveID
Corporation
PositiveID Corporation is a
life sciences tools and diagnostics company with an extensive
patent portfolio. PositiveID develops biological detection and
diagnostics systems, specializing in the development of
microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in
the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID
on Twitter, Facebook or LinkedIn.
On August 24, 2017,
PositiveID Corporation and its wholly-owned subsidiary PositiveID
Diagnostics, Inc. (collectively, the "Seller"), entered into an
Asset Purchase Agreement ("APA") with ExcitePCR Corporation.
Pursuant to the APA, at closing, the Seller will sell and deliver
to ExcitePCR all assets used in connection with the operation of
the FireflyDX technology. For more information on the APA, please
read PositiveID's Form 8-K filed on August 28, 2017, which can be
found here.
Statements
about PositiveID's future expectations, including the
likelihood that PositiveID's FireflyDX family of
products will provide automated, real-time
pathogen detection at the point of care/point of
need (POC/PON), faster and less expensively than existing
devices; the likelihood that FireflyDX's
onsite pathogen detection applications will
include human clinical, such as infectious disease, and
hospital acquired infections, global food and agricultural
screening, and biological warfare and biothreat
defense; constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as that
term is defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and PositiveID's actual results
could differ materially from expected results. These risks and
uncertainties include, without limitation, the Company's ability to
raise capital; the Company's ability to complete the
development, testing and commercialization of FireflyDX; the
Company's ability to close the APA with ExcitePCR; as well
as other risks. Additional information about these and other
factors that could affect the Company's business is set forth in
the Company's various filings with the Securities and Exchange
Commission, including those set forth in the Company's 10-K filed
on April 2, 2018, and 10-Qs filed on November 13, 2017,
August 14, 2017, and May 15, 2017, under the caption "Risk
Factors." The Company undertakes no obligation to update or release
any revisions to these forward-looking statements to reflect events
or circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contact:
PositiveID
Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com